Adi Diab, MD
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Adi Diab, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:49 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT02719015 · Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic MelanomaM.D. Anderson Cancer Center · withdrawn · Melanoma · principal investigator
- Ph1/Ph2NCT02706353 · APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic MelanomaM.D. Anderson Cancer Center · terminated · Melanoma · principal investigator
- Ph2NCT01827111 · Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic MelanomaM.D. Anderson Cancer Center · completed · Melanoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:49 UTC. The ranking covers the 200 most relevant of 11 PubMed records, and a shared surname and initials can bring in a namesake. All 11 on PubMed
- 132 citationsRCR 9.3
- The use of del Nido cardioplegia in adult cardiac surgery: A prospective randomized trial.J Thorac Cardiovasc Surg · 2018127 citationsRCR 8.6
- Modeling the Impact of Cardiopulmonary Irradiation on Overall Survival in NRG Oncology Trial RTOG 0617.Clin Cancer Res · 202065 citationsRCR 3.0
- A Phase 1 Study of the DNA-PK Inhibitor Peposertib in Combination With Radiation Therapy With or Without Cisplatin in Patients With Advanced Head and Neck Tumors.Int J Radiat Oncol Biol Phys · 202456 citationsRCR 7.5
- Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience.Int J Radiat Oncol Biol Phys · 201631 citationsRCR 1.0
- The impact of a multidisciplinary blood conservation protocol on patient outcomes and cost after cardiac surgery.J Thorac Cardiovasc Surg · 201727 citationsRCR 1.5
- Prospective US investigational device exemption trial of a sutureless aortic bioprosthesis: One-year outcomes.J Thorac Cardiovasc Surg · 201923 citationsRCR 1.7
- Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer.J Clin Oncol · 202514 citationsRCR 3.0
- Long-term Outcomes of Bevacizumab and Chemoradiation for Locoregionally Advanced Nasopharyngeal Carcinoma: A Nonrandomized Controlled Trial.JAMA Netw Open · 20236 citationsRCR 0.6